Search Results - massimiliano+bissa

3 Results

Sort By:

Chimeric VLP vaccines to Prevent HTLV-1 Infection

Summary: The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for Chimeric VLP Vaccines to Prevent HTLV-1 Infection. Description of Technology: There is currently no approved vaccine to prevent human T-cell leukemia virus type I (HTLV-1) infection, a highly oncogenic virus linked to serious diseases like adult...

Published: 11/10/2025 | Updated: 8/12/2025 | Inventor(s): Genoveffa Franchini, Sarkis Sarkis, Ramona Moles, Cynthia Masison, Massimiliano Bissa

Keywords(s):

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

Summary: NCI is seeking research co-development partners and/or licensees to evaluate, further develop or commercialize this high efficacy vaccine and microbicide combination for use against HIV. Description of Technology: Human immunodeficiency virus (HIV) remains a major global health challenge despite the advancement made in development of effective...

Published: 4/23/2026 | Updated: 8/2/2023 | Inventor(s): Genoveffa Franchini, Marjorie Robert-Guroff, Daniel Appella, Sabrina Helmold Hait, Mohammed Rahman, Massimiliano Bissa, Ettore Appella, Lisa Marie Jenkins, Isabela Silva De Castro

Keywords(s): Acquired Immuno-Deficiency Syndrome, ADCC, AIDS, Antibody-dependent Cellular Cytotoxicity, Efferocytosis, Envelope Glycoprotein 120, Envelope Variable Region, Franchini, gp120, HIV, Human Immunodeficiency Virus, Microbicide, SAMT-247, V1, Vaccine

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology, Application > Vaccines

Immunogens for Use in a High Efficacy HIV Vaccine

Summary: The Vaccine Branch is seeking statements of capability or interest from parties interested in licensing V1-deleted immunogens to further develop, evaluate, or commercialize an improved HIV vaccine. Description of Technology: Human immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): Genoveffa Franchini, Timothy Cardozo, Isabela Silva De Castro, Giacomo Gorini, Massimiliano Bissa, Manuel Becerra-Flores

Keywords(s): AIDS, Franchini, GLYCOPROTEIN, gp120, HIV, Human Immunodeficiency Virus, V1, V2, Vaccine, Variable Envelope Region

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Vaccines